Table 2 The NPs vaccine of picornavirus
From: Use of virus-like particles and nanoparticle-based vaccines for combating picornavirus infections
Virus | Antigen | Particle skeleton | Formation | Year of publication | Reference |
|---|---|---|---|---|---|
FMDV | B4T (B: VP1(Residues 136 aa-154 aa) T: 3A (Residues 21 aa-35 aa)) | B4T | Synthesised | 2008 | [130] |
| Â | P1, 3C | T4 bacteriophage | Escherichia coli | 2008 | [155] |
| Â | B4T, B2T | B4T, B2T | Synthesised | 2016 | [133] |
| Â | G-H loop | T7 bacteriophage | Escherichia coli | 2017 | [160] |
| Â | B4T, B2T (B: VP1(Residues 135 aa-160 aa) T: VP1 (Residues 21 aa-40 aa)) | B4T, B2T | Synthesised | 2017 | [134] |
| Â | VP1, G-H loop | Ferritin | B/IC: Sf-9 | 2020 | [34] |
| Â | Residues 16 aa-44 aa, 129 aa-160 aa and 200 aa-213 aa (VP1) | ADDomer | B/IC: Sf-9 | 2022 | [165] |
EV71 | Residues 208 aa-222 aa, 215 aa-218 aa, 213 aa-220 aa in VP1 | Ferritin | Escherichia coli | 2019 | [150] |